The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Novo Nordisk’s Lars Fruergaard Jørgensen will step down as CEO of the weight-loss drug maker following a steep decline in share price over the last year.The Danish drugmaker said it was a “mutual ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation ... seem to be weighing heavily on the stock — down less than 3% in trading ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Ozempic maker Novo Nordisk NOVO.B-2.41%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why NVO stock is a Buy.

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...

Earnings grew barely 14% last quarter -- and over the past year, the stock has lost roughly half its value. The board cited these "recent market challenges Novo Nordisk has been facing ...

"Considering the recent market challenges, the share price decline ... Read more about Novo Nordisk's stock moves and today's market action. After years of being known for its insulin and diabetes ...